These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 12504791)

  • 1. Advances in the pathophysiology of constitutive and inducible cyclooxygenases: two enzymes in the spotlight.
    Parente L; Perretti M
    Biochem Pharmacol; 2003 Jan; 65(2):153-9. PubMed ID: 12504791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual acting anti-inflammatory drugs: a reappraisal.
    Bertolini A; Ottani A; Sandrini M
    Pharmacol Res; 2001 Dec; 44(6):437-50. PubMed ID: 11735348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical expression of cyclooxygenase isoenzymes and downstream enzymes in human lung tumors.
    Ermert L; Dierkes C; Ermert M
    Clin Cancer Res; 2003 May; 9(5):1604-10. PubMed ID: 12738712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role and regulation of cyclooxygenase-2 during inflammation.
    Simon LS
    Am J Med; 1999 May; 106(5B):37S-42S. PubMed ID: 10390126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclooxygenases 1 and 2.
    Vane JR; Bakhle YS; Botting RM
    Annu Rev Pharmacol Toxicol; 1998; 38():97-120. PubMed ID: 9597150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Roles of cyclooxygenase (COX)-1 and COX-2 in prostanoid production by human endothelial cells: selective up-regulation of prostacyclin synthesis by COX-2.
    Caughey GE; Cleland LG; Penglis PS; Gamble JR; James MJ
    J Immunol; 2001 Sep; 167(5):2831-8. PubMed ID: 11509629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New insights into the role of COX 2 in inflammation.
    Gilroy DW; Colville-Nash PR
    J Mol Med (Berl); 2000; 78(3):121-9. PubMed ID: 10868474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinct functions of COX-1 and COX-2.
    Morita I
    Prostaglandins Other Lipid Mediat; 2002 Aug; 68-69():165-75. PubMed ID: 12432916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Arachidonic acid and prostaglandins, inflammation and oncology].
    Eschwège P; de Ledinghen V; Camilli T; Kulkarni S; Dalbagni G; Droupy S; Jardin A; Benoît G; Weksler BB
    Presse Med; 2001 Mar; 30(10):508-10. PubMed ID: 11307496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclo-oxygenase-2 inhibitors and the kidney: a case for caution.
    Noroian G; Clive D
    Drug Saf; 2002; 25(3):165-72. PubMed ID: 11945113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Current topics in the regulation of prostanoids-1. Inducible cyclooxygenase COX-2 and selective blockers].
    Ohara M; Sawa T
    Masui; 1998 Nov; 47(11):1325-32. PubMed ID: 9852696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential adverse effects of cyclooxygenase-2 inhibition: evidence from animal models of inflammation.
    Colville-Nash PR; Gilroy DW
    BioDrugs; 2001; 15(1):1-9. PubMed ID: 11437671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological analysis of cyclooxygenase-1 in inflammation.
    Smith CJ; Zhang Y; Koboldt CM; Muhammad J; Zweifel BS; Shaffer A; Talley JJ; Masferrer JL; Seibert K; Isakson PC
    Proc Natl Acad Sci U S A; 1998 Oct; 95(22):13313-8. PubMed ID: 9789085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of the induction of nitric oxide synthase and cyclo-oxygenase in rat aorta in organ culture.
    Bishop-Bailey D; Larkin SW; Warner TD; Chen G; Mitchell JA
    Br J Pharmacol; 1997 May; 121(1):125-33. PubMed ID: 9146896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.
    Chan CC; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Ford-Hutchinson AW; Forrest MJ; Gauthier JY; Gordon R; Gresser M; Guay J; Kargman S; Kennedy B; Leblanc Y; Leger S; Mancini J; O'Neill GP; Ouellet M; Patrick D; Percival MD; Perrier H; Prasit P; Rodger I
    J Pharmacol Exp Ther; 1999 Aug; 290(2):551-60. PubMed ID: 10411562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclooxygenase-2--10 years later.
    Hinz B; Brune K
    J Pharmacol Exp Ther; 2002 Feb; 300(2):367-75. PubMed ID: 11805193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.
    Riendeau D; Percival MD; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Falgueyret JP; Ford-Hutchinson AW; Gordon R; Greig G; Gresser M; Guay J; Kargman S; Léger S; Mancini JA; O'Neill G; Ouellet M; Rodger IW; Thérien M; Wang Z; Webb JK; Wong E; Chan CC
    Br J Pharmacol; 1997 May; 121(1):105-17. PubMed ID: 9146894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclooxygenase-2 inhibitors in tumorigenesis (Part II).
    Taketo MM
    J Natl Cancer Inst; 1998 Nov; 90(21):1609-20. PubMed ID: 9811310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The role of cyclooxygenase and prostaglandins in the pathogenesis of rheumatoid arthritis].
    Stańczyk J; Kowalski ML
    Pol Merkur Lekarski; 2001 Nov; 11(65):438-43. PubMed ID: 11852819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclooxygenases and the cardiovascular system.
    Mitchell JA; Kirkby NS; Ahmetaj-Shala B; Armstrong PC; Crescente M; Ferreira P; Lopes Pires ME; Vaja R; Warner TD
    Pharmacol Ther; 2021 Jan; 217():107624. PubMed ID: 32640277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.